Navigation Links
HiveMind Marketing to Enhance Search Results for Chemistry Solutions Leader ChemBridge
Date:1/26/2009

ill initially optimize the company's website for key search terms. Due to the time required in improving search engine results, HiveMind will supplement this organic search program with a pilot pay-per-click (PPC) program targeted at Google, Yahoo and MSN search engines. This two-pronged attack will not only test the viability of PPC to this technical audience and deliver short-term results, but also help the company achieve long-term search objectives.

"We're very excited about beginning this partnership with industry leader ChemBridge," said Tom Lauck, president and CEO of HiveMind. "Their dedication to serving the drug discovery industry is extremely impressive. We look forward to enhancing their profile on the Web and bringing them new leads while demonstrating our commitment to customer service."

About ChemBridge

ChemBridge Corporation is a leading global discovery chemistry services and screening compound library provider with an impeccable 15 year track record of quality and deliverability. ChemBridge is a privately held company with headquarters in San Diego, CA and with a state-of-the-art offshore discovery chemistry research site in Moscow, Russia. ChemBridge's discovery chemistry services track record includes multiple, multi-year collaborations with global pharmaceutical companies as well as collaborations with biotechnology companies. Over 500 pharmaceutical and biotechnology companies, universities and research institutions worldwide have taken advantage of ChemBridge's portfolio of 700,000 screening compounds and 10,000 building blocks.

About HiveMind Marketing, Inc.

Founded by Tom Lauck, a long-time Silicon Valley marketing practitioner, HiveMind Marketing, Inc. is a different kind of marketing firm that specializes in digital lead generation, helping mid-size organ
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
2. InterCure and Omron Healthcare (UK) Ltd. Announce Marketing Collaboration for Hypertension Market in United Kingdom
3. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
4. Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration
5. Phlo Affiliate Hires Chief Marketing Officer With Extensive Global Experience
6. Communicating Clinical Trial Data: Timing Remains Key Challenge for Marketing Teams
7. Bioenergy Life Science and Integrative Therapeutics, Inc. Form Exclusive Co-Marketing Alliance
8. Lantibio and TRB Chemedica Announce Licensing Agreement with Alcon for US Development and Marketing of Dry Eye Drug
9. Phlo Affiliate Names Director Of Marketing
10. Southern Research Expands Sales and Marketing Agreement with Absorption Systems to Service European Market
11. Natural Nutrition Launches International Marketing Campaign for New All Natural Analgesic: BLUE LIGHTNING(TM) Fast Pain Relief
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... July 31, 2014 SoundConnect ... collaboration company, is proud to announce the addition ... complements Adobe Connect’s elearning tools to quickly deploy ... content with training tools for desktop and mobile ... LMS is the perfect online training solution, enabling ...
(Date:7/30/2014)... 2014 Regulus Therapeutics Inc . (NASDAQ: ... discovery and development of innovative medicines targeting microRNAs, today ... for the quarter ended June 30, 2014 on Wednesday, ... Regulus will host a conference call ... pm Eastern Daylight Time to discuss its second quarter ...
(Date:7/30/2014)... , July 30, 2014 A ... evaluated the safety and efficacy of CSL Behring,s ... following kidney transplants in highly sensitized patients. C1-INH ... of the complement system. The study ... significant increases in the levels of complement components ...
(Date:7/30/2014)... Selexis SA , a serial innovation ... mammalian cell line development, announced today new data from ... presented at the 10th Annual Cell Line Development ... 10, 2014 at the Double Tree by Hilton Berkeley ... will be presented during an oral presentation: , Title: ...
Breaking Biology Technology:SoundConnect Enhances Portfolio with Adobe Connect Learning Management System (LMS) 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 3Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 2Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 3Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 2Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 3
... LEUVEN, Belgium and LUND, Sweden, September 7 ... Anticoagulant Into Phase,II Clinical Development ThromboGenics NV ... disease, and co-development partner, BioInvent,International (Nordic Exchange: BINV), ... initial follow-up of all volunteers,in the first Phase ...
... 6 Globally, approximately 418 billion,people are currently ... costs of hepatitis in the 21st century cannot ... a,new report by Kalorama Information. Paradoxically, despite ... necessary steps to contain hepatitis. Yet the incidence ...
... VRUS ) and Roche (OTC: RHHBY) announced ... the treatment of chronic hepatitis C,virus (HCV) will ... Hepatitis C,Virus and Related Viruses being held from ... of PSI-6130, is an oral cytidine nucleoside,analog polymerase ...
Cached Biology Technology:ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402 2ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402 3ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402 4ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402 5Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health 2Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses 2Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses 3Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses 4Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses 5
(Date:7/30/2014)... (ACS) announced today that David L. Kaplan, Ph.D., will ... & Engineering as editor-in-chief. With the first issue ... will feature high-quality research in the rapidly burgeoning field ... materials that interact with living or biological systems. , ... tremendous growth in the field of biomaterials over the ...
(Date:7/30/2014)... knows the shortest distance between two points is a ... sperm have been taking the familiar axiom to heart. ... thought to be intense, with each racing for the ... some species, sperm form cooperative groups that allow them ... , A new study, conducted by Heidi Fisher, a ...
(Date:7/30/2014)... the University of Helsinki and the Universitat Autnoma de ... morphological changes which have taken millions of years to ... development of mice teeth, induced in the laboratory, scientists ... those observed in the fossil registry of rodent species ... , To modify the development of their teeth, the ...
Breaking Biology News(10 mins):ACS Biomaterials Science & Engineering: Brand-new journal launches in 2015, names editor 2When cooperation counts 2When cooperation counts 3Scientists reproduce evolutionary changes by manipulating embryonic development of mice 2
... It,s long been known that alcohol use in ... birth defects, but researchers who study fetal alcohol syndrome ... disorder, detecting it early, or effectively treating it, say ... the issue of Developmental Neuroscience , four first-year ...
... How do we begin to understand what early life was ... planet shifted from an oxygen-free and probably ice-covered realm to ... who decodes the early record of life on Earth has ... a significantly clearer picture of this dynamic environment. Alison Olcott ...
... , THE WOODLANDS, Texas , June 15 ... company focused on discovering breakthrough treatments for human disease, announced today ... clinical trial of LX4211 for patients with type 2 ... June 19 – 22, 2010 in San Diego, ...
Cached Biology News:Little is understood about alcohol's effect on fetal development, Georgetown researchers say 2Little is understood about alcohol's effect on fetal development, Georgetown researchers say 3Delineating primary and secondary organic carbon in neoproterozoic glacial sediments 2Lexicon to Present Clinical Data for Diabetes Drug Candidate, LX4211, at Two Major Healthcare Conferences 2Lexicon to Present Clinical Data for Diabetes Drug Candidate, LX4211, at Two Major Healthcare Conferences 3Lexicon to Present Clinical Data for Diabetes Drug Candidate, LX4211, at Two Major Healthcare Conferences 4Lexicon to Present Clinical Data for Diabetes Drug Candidate, LX4211, at Two Major Healthcare Conferences 5
... Experion HighSens analysis kit for 25 chips ... perform high-sensitivity RNA analysis (at picogram levels) ... kit includes 25 RNA HighSens microfluidic chips, ... x 20 microliters RNA HighSens stain, 20 ...
Vitronectin Immunogen: Purified, full length, native human protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
... The Experion StdSens analysis kit for ... required to perform standard-sensitivity RNA analysis (at ... system. This kit includes 25 RNA StdSens ... gel, 2 x 20 microliters RNA StdSens ...
... 2-Methyl-3,5,7,8-tetrahydrothiopyrano[4,3-d]pyrimidine-4-one White ... GAS. A brain-permeable and water soluble pyrimidinone ... NAD + -competitive inhibitor of PARP (IC ... nM for rhPARP1 and rmPARP2, respectively) with ...
Biology Products: